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HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN: IM-
PROVED ENGRAFTMENT AND IMMUNE RECOVERY AFTER DEPLETION
OF T AND B CELLS INSTEAD OF POSITIVE SELECTION OF STEM CELLS?
Bader, P.1, Koehl, U.1, Soerensen, J.1, Lang, P.2, Kreyenberg, H.1,
Sach, G.1, Becker, M.1, Willasch, A.1, Esser, R.1, Handgretinger, R.2,
Klingebiel, T.1 1. University Children’s Hospital, Frankfurt am Main,
Germany; 2. University Children’s Hospital, Tuebingen, Germany.
During the past decade, transplantation of highly puriﬁed hap-
loidentical stem cells has become a well established treatment
procedure in the cure of many children with malignant and non-
malignant diseases. Positive enrichment of peripheral stem cells by
anti-CD34 or CD133 magnetic microbeads provides a graft pro-
foundly depleted of T and B cells facilitating engraftment without
inducing severe GVHD and EBV-lymphoproliferative disease. Al-
though transplanting “mega doses” (	106/kgBW) of positive en-
riched stem cells primary graft rejection, delayed immune recovery
and thereby an increased risk of transplant related mortality re-
mained major obstacles for the success of this approach. In 27
children with ALL who were transplanted with “mega-doses” (me-
dian: 16.46/kgBW; range 5.4–50.4) of positive enriched stem cells
from their HLA-haploidentical parents, primary engraftment
could be achieved in 88% and after reconditioning in 100% of
patients. All patients received G-CSF post transplant and achieved-
more than 500 ANC/l 12 days post transplant (range 8–24).
Immune recovery was obtained in all patients with a median time
to achieve more than 100 CD3 and CD4 cell/l of 67 and
101.2 days, respectively. Three year EFS of patients transplanted
in remission (n  21) was 0.43 ( 0.11). In contrast to positive
selection of stem cells, grafts after depletion of CD3/CD19 cells
consisted of remarkable amounts of effector cells such as NK-cells
(median number: 17.196/kgBW), dendritic cells, precursor T-cells,
and monocytes/granulocytes (median number: 446.456/kgBW).
These cells are expected to facilitate engraftment, speed up im-
mune reconstitution and provide also anti tumour activity in vivo.
So far nine children (ALL, n  4; AML, n  2; rhabdomyosar-
coma, n  2 and aplastic anaemia, n  1) were transplanted with
CD3/CD19 depleted peripheral stem cell grafts with a median
number of 10.66/kgBW CD 34 cells (range 4.6–20.0) at the
University Children’s Hospital Frankfurt. Without G-CSF, all
patients (100%) achieved rapid and sustained engraftment with
more than 500 ANC/l and more than 20.000 thrombocytes/l at
day 16.3 and 16.25, respectively. Median time to achieve more than
100 CD3 and CD4 cells/l was 53.0 and 52.5 days. Eight of
nine children are alive and well. One child with AML relapsed and
died on day 156 post transplant. Conclusions: Haploidentical
transplants using CD3/CD19 depleted grafts resulted in better and
more reliable engraftment with very rapid and potent immune
recovery.
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OUTCOME OF SECOND HEMATOPOIETIC STEM CELL TRANSPLANT IN
PEDIATRIC PATIENTS: A SINGLE INSTITUTION EXPERIENCE FROM
1975–2005
Cheng, J.C.1, Feig, S.A.1, Moore, T.B.1 1Mattel Children’s Hospital at
UCLA, Los Angeles, CA.
Purpose: To study the outcomes of second allogeneic hema-
topoietic stem cell transplant (HSCT) in pediatric patients for
malignant and non-malignant disorders. Furthermore, to iden-
tify predictors of favorable outcome in patients requiring second
HSCT. Methods: A retrospective analysis of 44 pediatric pa-
tients was performed studying recipients of a second allogeneic
HSCT from 1975–2005 at UCLA Medical Center. Twenty
patients with malignant disease (9 AML, 8 ALL, 2 CML, 1
Neuroblastoma) and 24 patients with non-malignant disease (14
severe aplastic anemia, 5 immunodeﬁciency, 5 other) were iden-
tiﬁed. Age, diagnosis, time to second transplant, graft-versus-
host disease severity, and conditioning regimen were studied as
possible predictors of favorable outcome. Results: The mean
age was 11.5 years (9.6 years for non-malignant group and 14.2
years for malignant group). The mean interval between trans-
plants was 12.3 months (20.5 for malignant, 5.6 for non-malig-
nant), 38/44 patients received 6/6 HLA-matched related do-
nors. A variety of conditioning regimens were used and GVHD
severity was variable. Survival to day 100 was comparable be-
tween malignant and non-malignant diseases (58% vs 56% re-
spectively; P  .84). However, despite a longer interval between
transplants, children with malignant diseases fared worse at 2
years (15% vs 42%; 95% CI: 2%–52%, P  .05). The leading
cause of death among patients with malignancies remained re-
lapsed disease. Age, GVHD severity and conditioning regimen
were not independently predictive of favorable outcome. Of
note, 5/5 matched unrelated donors did not survive after second
HSCT (2/5 preceded high-resolution typing availability). An
improvement in outcome over time was not appreciated. Con-
clusions: Second HSCT for pediatric patients remains associ-
ated with high morbidity and mortality. Similar to the adult
experience, children with non-malignant disease have improved
outcome after second transplant compared to relapsed malig-
nancy. There remain no clear predictors of favorable outcome
after second HSCT and despite improvements in supportive
care measures, outcomes remain poor. However, our experience
suggests that children who experience graft failure after initial
HSCT remain good candidates for second HSCT irrespective
of the time between transplants. Furthermore, careful consid-
eration should be given to justify the use of an unrelated donor
for second HSCT, as the outcome in our cohort or patients was
uniformly poor (Table 1).
Table 1. Survival After 2nd Allogeneic HSCT by Diagnosis
< 100 days > 100 days
2 yr Actuarial
Survival (%)
Severe Aplastic
Anemia 5 9 50
ALL 4 4 50
AML 3 6 22
CML 1 1 0
Immunodeficiency 1 4 60
Other Non-
Malignant 4 3 33
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HIGH INCIDENCE OF GRAFT FAILURE AND TRANSPLANT RELATED
MORTALITY (TRM) IN 50 CHILDREN RECEIVING UNRELATED UMBIL-
ICAL CORD BLOOD TRANSPLANTATION (UCBT) FOR NON-MALIGNANT
DISEASES
Bonﬁm, C.1, Setubal, D.1, Bitencourt, M.1, Funke, V.1, Ruiz, J.1,
Koliski, A.2, Medeiros, C.R.1, Zanis-Neto, J.1, Pasquini, R.1 1. Federal
University of Parana, Curitiba, PR, Brazil; 2. Pediatric Intensive Care
Unit UFPR, Curitiba, PR, Brazil.
In countries with a high level of miscegenation, unrelated
umbilical cord blood is a rapidly available source of hematopoi-
etic stem cells for children with malignant and non-malignant
diseases who lack a suitable HLA identical sibling. We report
the results in 50 children with non-malignant diseases submitted
to UCBT in our BMT center between 07/97 and 04/05. Median
age: 6 years (20 days–14 years). Diseases: Fanconi Anemia (FA):
29 patients (pts); Primary Immunodeﬁciencies (PID): 10 pts
(Wiskott Aldrich: 6 pts. SCID: 3pts; Kostmann syndrome: 1pt);
Severe Aplastic Anemia: 2 pts, Blackfan-Diamond Anemia: 2
pts, Dyskeratosis congenita: 1 pt; Leukodystrophies: 2 pts; Os-
teopetrosis: 4 pts; HLA Disparities: 6/6: 9 pts; 5/6: 24 pts and
4/6: 17pts. The majority of pts received a combination of Busul-
fan  Cyclophosphamide (CY)  ATG:12 pts or CY  Flu-
darabine  ATG: 23 pts. Five pts received a TBI based prepa-
ratory regimen. Other regimens: 10 pts. GVHD Prophylaxis:
cyclosporine (csa)  steroids: 35 pts; csa methotrexate: 10 pts;
csa  MMF /- steroids: 5 pts. TNC (before thawing): 2, 3
20, 1  107/kg (M: 6, 1). Twenty-two pts are alive with a
median follow-up of 606 days (range 156–2684) UCBT (FA: 12
pts; PID: 8 pts; Osteopetrosis: 2 pts). Eight pts died before D
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28 and were not evaluable for engraftment. Primary graft
failure occurred in 15 pts (35%) and 6 pts received a second
UCBT (only one pt is alive). Two other pts are alive with
autologous recovery (Osteopetrosis). Partial engraftment
(ANC 	 500/ul) occurred in 6 pts and all of them died. Acute
GVHD grade II-IV occurred in 15/28 pts (II: 2 pts, III: 8 pts;
IV: 5 pts) and C-GVHD in 11/20 pts (3 limited; 8 extensive).
Mucositis grade II-IV: 26 pts (III: 15 pts; IV: 3 pts). Arterial
hypertension and viral infections were also frequent complications.
VOD occurred in 4 pts (2 moderate; 1 severe). TRMwas very high in
this group reaching 46% (23 pts). Twenty-eight pts died in a median
of 38 days after UCBT (range 4–226). Main causes of death: infec-
tions: 20 pts (aggressive bacterial, fungal, and toxoplasmosis infec-
tions); bleeding: 3 pts; GVHD: 4 pts; and other: 1 pt. More than 70%
of our pts have bone marrow failures or osteopetrosis and this may
explain the high incidence of rejection and transplant relatedmortality
in this group of pts. Acute and chronic GVHD occurred with more
severity than expected for UCBT. We postulate that viral or other
infectious agents frequently found in our pts prior to transplant may
exacerbate this complication.
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STEM CELL TRANSPLANTATION IN 40 PTS WITH FANCONI ANEMIA
(FA): EXCELLENT SURVIVAL AND LOW TOXICITY FOR PTS WITH A
RELATED HLA IDENTICAL DONOR
Bonﬁm, C.1, Bitencourt, M.1, Funke, V.1, Setubal, D.1, Ruiz, J.1,
Seber, A.2, Pilonetto, D.1, Medeiros, C.R.1, Zanis-Neto, J.1,
Pasquini, R.1 1. Federal University of Parana, Curitiba, PR, Brazil; 2.
Instituto de Oncologia Pediatrica EPM, Sao Paulo, SP, Brazil.
SCT is the treatment of choice for FA patients (pts). These pts are
particularly hypersensitive to alkylating agents and radiation. In order
to decrease toxicity and maintain engraftment we have progressively
decreased the dose of CY during the last 20 years. In this study we
report our experience using the dose of CY 60 mg/kg in 40 pts
transplanted between 07/99–04/05. Median age : 9 years (5–29).
Previous blood transfusions: 0–101 (M: 5UI). Previous treatment with
androgens: 15/40 pts. All pts had pancytopenia and received either
unmanipulated bone marrow (39 pts) or cord blood (1 pt) from HLA
identical donors (siblings: 33 pts, other related: 7 pts). Preparatory
regimen consisted of CY 15 mg/kg/day  4. GVHD prophylaxis:
cyclosporine and methotrexate. TNC infused: 0, 97- 7, 3  108/kg
(M: 4, 05). The regimen was well tolerated with no transplant related
mortality (TRM). Thirty-eight pts (95%) are alive and well between
179–2250 days after SCT (M: 872 days). Median time to ANC
	500/ul: 19 days (11–57) and to platelets 	20.000/ul: 21 days (14–
57). Mucositis grades II–IV occurred in 92% of pts (II: 10 pts; III: 25
pts, IV: 1 pt). Mild VOD: 2 pts. Arterial hypertension was a frequent
complication. A-GVHD grade II-III occurred in 4/39 pts and C-
GVHD (extensive) in one pt. Primary graft failure (GF) occurred in
one pt (HLA identical sibling, 11 previous blood transfusions). He
received a second BMT from the same donor with no engraftment
and then a third BMT from another HLA identical sibling. He is now
187 days after BMT, independent of blood transfusion but with a slow
hematological recovery. Four pts (donors: 2 other related and 2
siblings) had a late GF on day 156, 202,  287, and 365 after
SCT. Three pts received a second SCT from the same donors and
they all engrafted. Two pts are alive and well with normal hemato-
logical counts on D 538 and 1203 after second SCT. Two pts
died: 1 after second SCT (day 98) due to A-GVHD, infection, and
cerebral venous sinus thrombosis. The other pt died on day918 due
to infections and complications related to rejection (29 years, 101
previous blood transfusions). We conclude that the use of CY 60
mg/kg in the preparatory regimen led to a better survival, no trans-
plant related mortality, and low incidence of both acute and chronic
GVHD. Graft failure occurred in 5 pts but 3 pts were rescued with
another transplant. This regimen can be offered safely to pts with
Fanconi anemia who have a related HLA identical donor.
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SINGLE CENTER EXPERIENCE OF UNRELATED UMBILICAL CORD
BLOOD TRANSPLANTATION (UCBDT) FOR ACUTE MYELOID LEUKEMIA
(AML) IN 97 PEDIATRIC PATIENTS: IMPACT OF DISEASE STATUS AND
CYTOREDUCTIVE REGIMEN
Prasad, V.K.1, Wu, J.2, Parikh, S.H.1, Driscoll, T.A.1, Szabolcs, P.1,
Martin, P.L.1, Carter, S.2, Kurtzberg, J.1 1. Pediatric Blood and
Marrow Transplantation Program, Duke University Medical Center,
Durham, NC; 2. Emmes Corporation, Rockville, MD.
Banked, unrelated donor umbilical cord blood (UCB) increases
access to transplant by providing a source of hematopoietic stem
cells for patients (pts) lacking a family donor. We present outcomes
of 97 pediatric (ped) AML pts transplanted from 1995–2005. At
transplant, 51 pts were in Relapse or Refractory (RR) disease while
46 were in CR1/2 (CR). By low resolution HLA A/B  high-
resolution DRB1 typing, UCB units transplanted to RR pts were
3/6 (18%), 4/6 (45%), 5/6 (31%), or 6/6 (6%) matched and those
to CR pts were 4/6 (67%) or 5/6 (33%). The median age of RR and
CR pts was 8.4 and 9.4 years. Ethnic minorities comprised 35.3%
of RR and 34.8% of CR pts. Thirteen RR and 2 CR had prior auto-
or allo-transplants. The median total nucleated cell (TNC) doses
infused in RR and CR pts were 4.4 and 3.8  107/kg. All pts
received myeloablative regimens. RR pts receiving Melphalan con-
taining regimens (Bu/Mel/ATG or Flu/Mel/ATG or TBI/Mel/
ATG) were grouped as RR_Melve (n  33) and the rest receiving
TBI/Cy/ATG as RR_Melve (n  18). CR pts receiving TBI
containing regimens (TBI/Cy/ATG or TBI/Mel/ATG) were
grouped as CR_TBIve (n  29) and the rest receiving Bu/Mel/
ATG or Flu/Mel/ATG or Flu/Bu/Mel/ATG as CR_TBI-ve (n 
17). GVHD prophylaxis was Cyclosporinemethylprednisone in
94.8% The TNC dose, HLA match level, age, minority propor-
tion, and GVHD prophylaxis were similar between the RR and CR
pts. The probabilities of overall survival (OS) were estimated by
Kaplan-Meier analysis and compared using log-rank test. The 3
year probability of OS in the RR and CR was 28% and 48%.
AGVHD (Grade 2–4) was seen in 21.6% of RR and 21.7% of CR
pts and CGVHD in 6% and 7% of RR and CR pts. Deaths were
due to relapse, infection, and organ failure Within RR and CR the
impact of cytoreductive regimen was signiﬁcant. Three year prob-
ability of OS in CR_TBIve was signiﬁcantly higher (60%) than of
CR_TBIve (28%) pts (P  .014). The 3 year probability of OS in
RR_Melve was higher (39%) than of RR_Melve (11%) but the
difference did not reach statistical signiﬁcance(P  .132). We
conclude that for ped pts with AML lacking a family donor, UCB
is an excellent source of hematopoietic stem cells for those in
remission as well as those with high risk relapsed or refractory
disease. Cytoreductive regimen inﬂuences outcomes in both
groups of pts with more favorable outcomes in CR pts prepared
with TBI containing regimens and in refractory/relapsed pts pre-
pared with melphalan containing regimens.
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EVALUATION OF SECOND TRANSPLANTS FOLLOWING GRAFT FAILURE
IN UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT)
Merchant, M.1, Duerst, R.1,2, Olszewski, M.1, Huang, W.1,
Jacobsohn, D.1,2, Kletzel, M.1,2 1. Children’s Memorial Hospital, Chi-
cago, IL; 2. Robert H. Lurie Cancer Center, Feinberg School of Medicine,
Northwestern University, Chicago, IL.
Objective: To evaluate the results of second allogeneic trans-
plantation after UCBT failed to engraft. Methods: Between No-
vember 1995 and July 2005, 116 UCBT were carried out at
Children’s Memorial Hospital of which 18 required second trans-
plantation (from failure to engraft, or relapse). Ten patients with
graft failure following a myeloablative cytoreduction regimen sub-
sequently received another transplant of unrelated cord blood (n
7), matched sibling marrow (n  1), marrow from a haploidentical
sibling (n  1), or matched sibling peripheral stem cells (n  1).
Underlying diseases for these 10 patients included AML (n  4),
Thalassemia (n  2), and 1 each of Myelodysplasia, Fanconi ane-
mia, Osteopetrosis, and ALL. Preparative conditioning prior to the
second transplant included Fludarabine 120–150 mg/m2 (n  5);
VP, Cy (n  2), or ATG (n  1). The 2 Thalassemia patients
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